Biotech company Thermo Fisher Scientific has dismissed its patent infringement action against DeNovix, US-based instrumentation business.
Kenneth Frazier, the CEO of Merck, is one of three chief executives to step down from US President Donald Trump’s manufacturing council.
A US judge has ruled that five patents owned by Pfizer are not invalid as obvious, in a dispute over a generic produced by Mylan.
Jazz Pharmaceuticals has taken issue with a trademark application filed by Novartis in the US, filing an opposition at the Trademark Trial and Appeal Board.
The US Court of Appeals for the Federal Circuit has rejected a request by Amgen to compel discovery from Hospira over a biosimilar.
The US International Trade Commission has instituted a probe into CSL Behring, a biopharmaceutical company.
Big pharma is confronted with little competition in Mexico, with 22 drugs facing no generic rivals in the country.
The US Food and Drug Administration finalised 46 product-specific bioequivalence guidances in August.
Biopharmaceutical company Dermira has acquired the licensing rights to lebrikizumab, a treatment for atopic dermatitis, from Roche.
Biopharma company Coherus BioSciences has filed a petition for inter partes review of a patent controlled by Amgen.